Adimmune Corporation

Taiwan Stock Exchange 4142.TW

Adimmune Corporation EBITDA Margin for the year ending December 31, 2023: -28.71%

Adimmune Corporation EBITDA Margin is -28.71% for the year ending December 31, 2023, a -245.87% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Adimmune Corporation EBITDA Margin for the year ending December 31, 2022 was 19.68%, a 26.71% change year over year.
Adimmune Corporation EBITDA Margin for the year ending December 31, 2021 was 15.53%, a -79.94% change year over year.
Adimmune Corporation EBITDA Margin for the year ending December 31, 2020 was 77.42%, a 3,119.51% change year over year.
Adimmune Corporation EBITDA Margin for the year ending December 31, 2019 was -2.56%, a 94.33% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Taiwan Stock Exchange: 4142.TW

Adimmune Corporation

CEO	Mr. Chi-Hsien Chan
IPO Date	May 3, 2012
Location	Taiwan
Headquarters	No. 3, Tanxing Road
Employees	564
Sector	Health Care
Industries Vaccines Pharmaceuticals

Description

Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.

Key trends

Past 5 years